{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:34:30Z","timestamp":1791246870953,"version":"4.1.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2015,4,22]],"date-time":"2015-04-22T00:00:00Z","timestamp":1429660800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1007\/s10072-015-2221-2","type":"journal-article","created":{"date-parts":[[2015,4,21]],"date-time":"2015-04-21T15:50:28Z","timestamp":1429631428000},"page":"1633-1641","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Efficacy and adverse effects of memantine treatment for Alzheimer\u2019s disease from randomized controlled trials"],"prefix":"10.1007","volume":"36","author":[{"given":"Jue","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,4,22]]},"reference":[{"key":"2221_CR1","doi-asserted-by":"crossref","first-page":"365","DOI":"10.2165\/00002512-199915050-00004","volume":"15","author":"L Fratiglioni","year":"1999","unstructured":"Fratiglioni L, Ronchi DD, Aguero-Torres H (1999) Worldwide prevalence and incidence of dementia. Drug Aging 15:365\u2013375","journal-title":"Drug Aging"},{"key":"2221_CR2","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1016\/S0140-6736(05)67889-0","volume":"366","author":"CP Ferri","year":"2005","unstructured":"Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, Hall K, Hasegawa K, Hendrie H, Huang Y, Jorm A, Mathers C, Menezes PR, Rimmer E, Scazufca M (2005) Global prevalence of dementia: a Delphi consensus study. Lancet 366:2112\u20132117","journal-title":"Lancet"},{"key":"2221_CR3","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0028-3908(99)00019-2","volume":"38","author":"CG Parsons","year":"1999","unstructured":"Parsons CG, Danysz W, Quack G (1999) Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist\u2014a review of preclinical data. Neuropharmacology 38:735\u2013767","journal-title":"Neuropharmacology"},{"key":"2221_CR4","doi-asserted-by":"crossref","unstructured":"Burke D (2012) ACP Journal Club. Donepezil or memantine improved cognitive functioning in moderate-to-severe Alzheimer disease. Ann Intern Med 156:JC6\u201310","DOI":"10.7326\/0003-4819-156-12-201206190-02010"},{"key":"2221_CR5","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jalz.2006.10.004","volume":"3","author":"RS Doody","year":"2007","unstructured":"Doody RS, Tariot PN, Pfeiffer E, Olin JT, Graham SM (2007) Meta-analysis of six-month memantine trials in Alzheimer\u2019s disease. Alzheimers Dement 3:7\u201317","journal-title":"Alzheimers Dement"},{"key":"2221_CR6","doi-asserted-by":"crossref","first-page":"445","DOI":"10.3233\/JAD-130395","volume":"36","author":"Z Yang","year":"2013","unstructured":"Yang Z, Zhou X, Zhang Q (2013) Effectiveness and safety of memantine treatment for Alzheimer\u2019s disease. J Alzheimers Dis 36:445\u2013458","journal-title":"J Alzheimers Dis"},{"key":"2221_CR7","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1212\/WNL.34.7.939","volume":"34","author":"G McKhann","year":"1984","unstructured":"McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer\u2019s disease: report of the NINCDS-ADRDAWork Group under the auspices of Department of Healthand Human Services Task Force on Alzheimer\u2019s Disease. Neurology 34:939\u2013944","journal-title":"Neurology"},{"key":"2221_CR8","volume-title":"DSM-IV-TR: diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2000","unstructured":"American Psychiatric Association (2000) DSM-IV-TR: diagnostic and Statistical Manual of Mental Disorders, 4th edn. American Psychiatric Press, Washington, DC","edition":"4"},{"key":"2221_CR9","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1056\/NEJMoa013128","volume":"348","author":"B Reisberg","year":"2003","unstructured":"Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ (2003) Memantine in moderate-to-severe Alzheimer\u2019s disease. N Engl J Med 348:1333\u20131341","journal-title":"N Engl J Med"},{"key":"2221_CR10","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1001\/jama.291.3.317","volume":"291","author":"PN Tariot","year":"2004","unstructured":"Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I (2004) Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 291:317\u2013324","journal-title":"JAMA"},{"key":"2221_CR11","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1097\/WAD.0b013e318065c495","volume":"21","author":"CH Dyck van","year":"2007","unstructured":"van Dyck CH, Tariot PN, Meyers B, Malca Resnick E (2007) A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease. Alzheimer Dis Assoc Disord 21:136\u2013143","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"2221_CR12","doi-asserted-by":"crossref","first-page":"e35185","DOI":"10.1371\/journal.pone.0035185","volume":"7","author":"C Fox","year":"2012","unstructured":"Fox C, Crugel M, Maidment I, Auestad BH, Coulton S, Treloar A, Ballard C, Boustani M, Katona C, Livingston G (2012) Efficacy of memantine for agitation in Alzheimer\u2019s dementia: a randomised double-blind placebo controlled trial. PLoS One 7:e35185","journal-title":"PLoS One"},{"key":"2221_CR13","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1097\/JCP.0b013e31829a876a","volume":"33","author":"T Wang","year":"2013","unstructured":"Wang T, Huang Q, Reiman EM, Chen K, Li X, Li G, Lin Z, Li C, Xiao S (2013) Effects of memantine on clinical ratings, fluorodeoxyglucose positron emission tomography measurements, and cerebrospinal fluid assays in patients with moderate to severe Alzheimer dementia: a 24-week, randomized, clinical trial. J Clin Psychopharmacol 33:636\u2013642","journal-title":"J Clin Psychopharmacol"},{"key":"2221_CR14","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s40263-013-0077-7","volume":"27","author":"GT Grossberg","year":"2013","unstructured":"Grossberg GT, Manes F, Allegri RF, Gutierrez-Robledo LM, Gloger S, Xie L, Jia XD, Pejovic V, Miller ML, Perhach JL, Graham SM (2013) The safety, tolerability, and efficacy of once-daily memantine (28\u00a0mg): a multinational, randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe Alzheimer\u2019s disease taking cholinesterase inhibitors. CNS Drugs 27:469\u2013478","journal-title":"CNS Drugs"},{"key":"2221_CR15","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1017\/S1041610213000239","volume":"25","author":"N Herrmann","year":"2013","unstructured":"Herrmann N, Gauthier S, Boneva N, Lemming OM (2013) A randomized, double-blind, placebo-controlled trial of memantine in a behaviorally enriched sample of patients with moderate-to-severe Alzheimer\u2019s disease. Int Psychogeriatr 25:919\u2013927","journal-title":"Int Psychogeriatr"},{"key":"2221_CR16","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2174\/156720508783884576","volume":"5","author":"AP Porsteinsson","year":"2008","unstructured":"Porsteinsson AP, Grossberg GT, Mintzer J, Olin JT (2008) Memantine treatment in patients with mild to moderate Alzheimer\u2019s disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. Curr Alzheimer Res 5:83\u201389","journal-title":"Curr Alzheimer Res"},{"key":"2221_CR17","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1136\/jnnp.2007.141648","volume":"79","author":"R Schmidt","year":"2008","unstructured":"Schmidt R, Ropele S, Pendl B, Ofner P, Enzinger C, Schmidt H, Berghold A, Windisch M, Kolassa H, Fazekas F (2008) Longitudinal multimodal imaging in mild to moderate Alzheimer disease: a pilot study with memantine. J Neurol Neurosurg Psychiatry 79:1312\u20131317","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2221_CR18","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1097\/01.JGP.0000224350.82719.83","volume":"14","author":"ER Peskind","year":"2006","unstructured":"Peskind ER, Potkin SG, Pomara N, Ott BR, Graham SM, Olin JT, McDonald S (2006) Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial. Am J Geriatr Psychiatry 14:704\u2013715","journal-title":"Am J Geriatr Psychiatry"},{"key":"2221_CR19","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3233\/JAD-2011-110947","volume":"28","author":"J Saxton","year":"2012","unstructured":"Saxton J, Hofbauer RK, Woodward M, Gilchrist NL, Potocnik F, Hsu HA, Miller ML, Pejovic V, Graham SM, Perhach JL (2012) Memantine and functional communication in Alzheimer\u2019s disease: results of a 12-week, international, randomized clinical trial. J Alzheimers Dis 28:109\u2013118","journal-title":"J Alzheimers Dis"},{"key":"2221_CR20","doi-asserted-by":"crossref","first-page":"459","DOI":"10.3233\/JAD-2011-111616","volume":"29","author":"D Wilkinson","year":"2012","unstructured":"Wilkinson D, Fox NC, Barkhof F, Phul R, Lemming O, Scheltens P (2012) Memantine and brain atrophy in Alzheimer\u2019s disease: a 1-year randomized controlled trial. J Alzheimers Dis 29:459\u2013469","journal-title":"J Alzheimers Dis"},{"key":"2221_CR21","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3233\/JAD-2008-13110","volume":"13","author":"S Bakchine","year":"2008","unstructured":"Bakchine S, Loft H (2008) Memantine treatment in patients with mild to moderate Alzheimer\u2019s disease: results of a randomised, double-blind, placebo-controlled 6-month study. J Alzheimers Dis 13:97\u2013107","journal-title":"J Alzheimers Dis"},{"key":"2221_CR22","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1159\/000102568","volume":"24","author":"B Winblad","year":"2007","unstructured":"Winblad B, Jones RW, Wirth Y (2007) St\u00a8offler A, M\u00a8obius HJ: Memantine in moderate to severe Alzheimer\u2019s disease: A meta-analysis of randomised clinical trials. Dement Geriatr Cogn Disord 24:20\u201327","journal-title":"Dement Geriatr Cogn Disord"},{"key":"2221_CR23","doi-asserted-by":"crossref","unstructured":"Lockhart IA, Orme ME, Mitchell SA (2011) The efficacy of licensed-indication use of donepezil and memantine monotherapies for treating behavioural and psychological symptoms of dementia in patients with Alzheimer\u2019s disease: systematic review and meta-analysis. Dement Geriatr Cogn Disord Extra 1:212\u2013227","DOI":"10.1159\/000330032"},{"key":"2221_CR24","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1093\/ije\/21.5.837","volume":"21","author":"DJ Newell","year":"1992","unstructured":"Newell DJ (1992) Intention-to-treat analysis: implications for quantitative and qualitative research. Int J Epidemiol 21:837\u2013841","journal-title":"Int J Epidemiol"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-015-2221-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10072-015-2221-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-015-2221-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,23]],"date-time":"2019-08-23T21:57:08Z","timestamp":1566597428000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10072-015-2221-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,22]]},"references-count":24,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["2221"],"URL":"https:\/\/doi.org\/10.1007\/s10072-015-2221-2","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,22]]}}}